Mechanism of action
header logo

Terms of Use

The information contained on this site is for healthcare professionals only.

I am a healthcare professional from
Choose a Country ▼

REPATHA®
APPROVED TO
REDUCE
CARDIOVASCULAR
RISK1

Mechanism of action

Repatha® is a fully human monoclonal antibody that binds selectively and with high affinity to circulating PCSK9.1 This prevents PCSK9 from binding to the LDL receptor (LDLR) on the liver cell surface, thus preventing PCSK9-mediated LDLR degradation.1 Increasing liver LDLR levels causes blood LDL-C levels to decrease.1

With Repatha®

Discover how Repatha® works
Watch a short animated video to learn more about how PCSK9 inhibition with Repatha® delivers intensive LDL-C reductions.

*In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl.
25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EVOPACS = EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; LDL-C = Low-density lipoprotein cholesterol; LDLR = LDL receptor; MI = Myocardial infarction; PCSK9 = Protein convertase subtilisin/kexin type 9; RRR = Relative risk reduction.
  1. Repatha® (evolocumab) Summary of Product Characteristics. Last revised: April 2020.
  2. Gencer B, et al. JAMA Cardiol. 2020; Online first. doi:10.1001/jamacardio.2020.0882.

By clicking the 'DOWNLOAD' button below you will immediately begin downloading the Reporting Systems Appendix
Return to previous page DOWNLOAD